Phase 1 Study of ACR-2316 in Specific Advanced Solid Tumors

PHASE1RecruitingINTERVENTIONAL
Enrollment

90

Participants

Timeline

Start Date

October 8, 2024

Primary Completion Date

August 12, 2026

Study Completion Date

December 12, 2026

Conditions
Specific Advanced Solid Tumors
Interventions
DRUG

ACR-2316

ACR-2316 is an experimental drug

Trial Locations (15)

10461

RECRUITING

Montefiore Medical Centre, The Bronx

14203

RECRUITING

Roswell Park Comprehensive Cancer Center, Buffalo

22031

RECRUITING

Next Virginia, Fairfax

28078

RECRUITING

Carolina BioOncology Institute, Huntersville

34232

RECRUITING

Florida Cancer Specialist, Sarasota

37067

RECRUITING

Tennesse Oncology, Franklin

48109

RECRUITING

University of Michigan, Ann Arbor

77054

RECRUITING

The University of Texas MD Anderson Cancer Center, Houston

78229

RECRUITING

NEXT Oncology, San Antonio

80218

RECRUITING

Denver Health One, Denver

85016

RECRUITING

HonorHealth Cancer Care, Phoenix

90212

RECRUITING

Precision NextGen Oncology & Research Center, Beverly Hills

92663

RECRUITING

Hoag Memorial Hospital Presbyterian, Newport Beach

02215

RECRUITING

Beth Israel Deaconess Medical Center, Boston

02903

RECRUITING

Rhode Island Hospital, Providence

Sponsors
All Listed Sponsors
lead

Acrivon Therapeutics

INDUSTRY

NCT06667141 - Phase 1 Study of ACR-2316 in Specific Advanced Solid Tumors | Biotech Hunter | Biotech Hunter